Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as ...

Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

Research published in the Annals of Internal Medicine examined the performance of fecal immunochemical tests in detecting colorectal cancer and advanced adenomas. 1. A 10 µg/g threshold resulted in a ...

In 2024, the FDA approved at-home blood and stool tests for colorectal cancer screenings. In October, a second iteration of the at-home stool test was approved. Access: Patients are 20.29% more likely ...

cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...

Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...